EFFICACY AND SAFETY OF PROLONGED MAINTENANCE WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NHL: RESULTS OF THE PHASE III MABCUTE STUDY
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.43_2630
Abstract: Pharma/Astra Zeneca, Celgene. Janssen; Honoraria: Abbvie, Acerta Pharma/Astra Zeneca, Celgene. Janssen, Gilead Sciences, Roche/Genentech, TG Therapeutics; Research Funding: Acerta Pharma/Astra Zeneca, Janssen, Celgene. Trneny, M: Consultant Advisory Role: Takeda, BMS, Incyte, Abbvie, Amgen, Roche, Gilead,… read more here.
Keywords: hematology; advisory role; celgene; consultant advisory ... See more keywords
IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.69_2629
Abstract: Position: F. Hoffmann La Roche Ltd; Stock Ownership: F. Hoffmann La Roche Ltd. Ritgen, M: Consultant Advisory Role: Roche, Abbvie; Research Funding: Roche, Abbvie; Other Remuneration: Personal Fees: Roche. Tausch, E: Consultant Advisory Role: Roche;… read more here.
Keywords: advisory role; remuneration; roche abbvie; consultant advisory ... See more keywords